CLINICAL EVENTS CALENDAR
Non-Accredited Education
 CLINICAL EXPERIENCE WITH A NEW HYBRID CORONARY WIRE On Demand Web ArchiveNon-Accredited Target Audience: Physicians, nurses, and technologists. This activity is supported by an educational grant from Terumo Medical Corporation. |
Invasive Cardiology News Wire
ESC News: Assessing the Risks of bleeding from Antithrombotic Therapy
Stockholm, Sweden, 29 August: Antithrombotic therapy using antiplatelet and anticoagulant agents is the cornerstone of treatment for acute and chronic coronary artery disease (CAD), yet it is also associated with an increased risk of bleeding. It is paradoxical that elderly patients, the most likely population to develop CAD, are those that suffer most from bleeding complications. Research has been carried out at OLVG Hospital in the Netherlands into the stratification of risk for all patients requiring this type of therapy.
ESC News: Results from the ATOLL study
Stockholm, Sweden, 30 August: Results from ATOLL, a phase 3 randomised trial comparing two anticoagulants in primary PCI for ST elevation MI, show that the low molecular weight heparin enoxaparin may provide better outcomes in such cases than the traditionally used unfractionated heparin.
The former, explained principal investigator Professor Gilles Montalescot from the Cardiology Department of Pitié-Salpêtrière University Hospital, Paris, has already been associated with a 57% relative risk reduction of major bleeding when compared with unfractionated heparin (UFH) in a large randomised study performed in elective PCI. But so far, primary PCI for STEMI has traditionally been supported by unfractionated heparin. The aim of the ATOLL study was to compare head-to-head intravenous enoxaparin with UFH in patients undergoing PCI for STEMI. "The time has come to acknowledege that there is better anticoagulation than UFH in PCI, primary PCI included" said Professor Montalescot.
ESC News: The ISAR-REACT 3A Trial
Date :
30 Aug 2010
Stockholm, Sweden, 30 August: With both bleeding und thrombotic complications having a negative effect on PCI outcomes, increasing efforts have been made to improve PCI anticoagulation regimens. Although unfractionated heparin has been the standard anti-thrombotic agent in interventional cardiology for decades, there is still no solid evidence from large clinical trials to guide its dosing during PCI.
Two dosing regimens are currently recommended: an initial bolus dose of 70-100 U/kg bodyweight followed by additional boluses under ACT (activated clotting time) guidance; and a single bolus dose of 100 U/kg (more common in Europe). Recently, the direct thrombin inhibitor bivalirudin has emerged as an effective alternative treatment to heparin in patients undergoing PCI.
ESC News: Results from FUTURA/OASIS 8 trial
The safety of two intravenous heparin doses as adjunct to PCI in ACS patients treated with fondaparinux
Results from the FUTURA/OASIS 8 study presented today at the ESC Congress provide initial evidence that a low dose of unfractionated heparin does not reduce the incidence of bleeding or vascular complications in PCI patients treated with the anticoagulant fondaparinux. Findings showed that the rates of peri-PCI major bleeding were 1.4% in those given low dose heparin and 1.2% the standard dose.
“There has been a widely held view that lowering heparin dose also lowers bleeding rates during PCI," said principal investigator Dr Sanjit Jolly, Assistant Professor of Medicine in the Michael G. DeGroote School of Medicine at McMaster University, "but randomised trial data have been lacking. Now, results from this study challenge that view."
Portable ECMO Machine Sustains Patients in Transport for the First Time in the U.S.
HOUSTON (Aug. 26, 2010) - The Methodist Hospital in Houston is the only hospital in the U.S. using a portable ECMO machine to successfully transport patients in acute cardiogenic shock.
Physicians at the Methodist DeBakey Heart & Vascular Center at The Methodist Hospital started using the portable Lifebridge device, an extra corporeal membrane oxygenator, which provides complete cardiopulmonary support during the life-threatening moments of cardiogenic shock, when the heart cannot sustain blood flow to the body’s organs.
“These patients would not be alive right now, if not for our access to this new device,“ said Dr. Wade Fischer, cardiothoracic surgeon with the Methodist DeBakey Heart & Vascular Center and director of the ECMO program at Methodist.
Successful Implant of AngelMed Cardiac Monitor and Alert System
Technology designed to alert patient to the need for medical attention and improve heart attack survival rates in high-risk patients
SALINAS, Calif., Aug. 25 /PRNewswire-USNewswire/ -- Research that got underway today at Salinas Valley Memorial Healthcare System could help alert patients to an impending heart attack.
At 8:45 A.M. today, Salinas Valley Memorial Healthcare System launched its clinical participation in a national trial for the AngelMed Guardian System, when physicians implanted the Cardiac Monitor and Alert System into a high-risk heart patient. The AngelMed Guardian is designed to track significant changes in the heart's signals and let the patient know when it is time to contact the doctor, or even head straight to the emergency room.
Integra Issues URGENT Worldwide Recall of NeuroBalloon(TM) Catheter
August 20, 2010 – Integra LifeSciences Corporation, Plainsboro, New Jersey, has initiated a worldwide recall of the NeuroBalloon Catheter. There were a total of 1,924 units distributed, 258 in the United States of America 1,586 in the European Union and 80 in countries. A total of eight (8) complaints regarding the inflation or deflation of the NeuroBalloon Catheter were received by Integra. All complaints occurred outside the United States. No patient injuries have been reported. As a result of the investigation performed by Integra, it was determined that this condition could exist during
ACCF Joins SCAI as New Partner in Accreditation of Cardiovascular Facilities
Accreditation for Cardiovascular Excellence (ACE) currently accepting applications for accreditation of carotid artery stenting programs
WASHINGTON, DC (August 19, 2010) – The Society for Cardiovascular Angiography and Interventions (SCAI) and the American College of Cardiology Foundation (ACCF) today announced an agreement to jointly sponsor the Accreditation for Cardiovascular Excellence (ACE) organization. Founded by SCAI in May 2010, ACE provides professional review of facilities where invasive cardiac and endovascular procedures are performed and will accredit those that achieve p
FDA Advisory Committee recommends US FDA approval of Brilinta (ticagrelor) for Acute Coronary Syndromes
July 29, 2010 — AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca’s investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes (ACS).
The Advisory Committee voted as follows:
Questions to the Advisory Committee
1. Should ticagrelor be approved for reduction of thrombotic events in patients with nonST-elevation (NSTEMI) and ST-elevation (STEMI) ACS intended to be managed by PCI?
Yes: 7 No: 1 Abstain: 0
2
Medtronic Launches Novel Clinical Trial Evaluating Spinal Cord Stimulation Therapy for Heart Failure
Defeat‐HF Trial Aims to Slow HF Progression with Neurostimulation
MINNEAPOLIS – July 29, 2010 – Medtronic, Inc. (NYSE: MDT) today announced the global launch of the Defeat‐HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical trial. It is the industry’s first prospective, randomized study evaluating the clinical feasibility of spinal cord stimulation (SCS), or neurostimulation, to improve clinical signs and symptoms of heart failure.
More than 5 million Americans and 22 million people worldwide have heart fa
Cardiology Blogs
All Subscriptions are FREE to qualified cardiology professionals
- Subscribe to:
- Journal
- Digital Journal
- E-News
- RSS feed
Anytown, California
Press Release
— Bethlehem, Pennsylvania – Invatec received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in October to market its Mo.Ma Ultra Proximal Cerebral Protection Device for use during carotid artery stenting (CAS). The device effectively reduces and captures debris released during the stenting procedure to prevent it from traveling to the brain, where it has the potential to cause a stroke.
CME Showcase
 The Use of Remote Robotic Navigation in Complex Arrhythmias Complimentary Accredited Web Archive This activity is designed for electrophysiologists and EP allied professionals. Diagnosing Coronary Artery Disease: Advanced Cardiovascular Imaging Solutions  New Standards of Care for CRMD Antibiotic Protection Complimentary CME Accredited Webcast Dates: November 18, 2008 Time: 6:00 pm ET November 19, 2008 Time: 3:00 pm ET This activity is sponsored by the North American Center for Continuing Medical Education. |
REVIEW OUR OTHER
CARDIOLOGY BRANDS Check out our other resources for healthcare professionals of all specialties.
